Aligos Therapeutics (ALGS) Other Operating Expenses (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Other Operating Expenses came in at $811000.0 in Q1 2026, down 7.84% YoY from $880000.0 in Q1 2025, and up 8.13% on a QoQ basis from $750000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Other Operating Expenses (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Other Operating Expenses data on file, last reported at $811000.0 in Q1 2026.
- Quarterly Other Operating Expenses fell 7.84% year-over-year to $811000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 2.8% YoY) and the FY2025 annual result came in at $3.9 million, down 10.99% from the prior year.
- Other Operating Expenses climbed to $811000.0 in Q1 2026, from $750000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $1.6 million in Q1 2024 to a low of -$5000.0 in Q1 2022.
- A 5-year average of $837176.5 and a median of $880000.0 in 2025 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses sank 104.5% — and 2023, when it surged 20140.0%.
- Tracing ALGS's Other Operating Expenses over 5 years: stood at $845000.0 in 2022, then tumbled by 71.12% to $244000.0 in 2023, then jumped by 134.84% to $573000.0 in 2024, then surged by 30.89% to $750000.0 in 2025, then increased by 8.13% to $811000.0 in 2026.
- The last three Other Operating Expenses figures came in at $811000.0 (Q1 2026), $750000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Aligos Therapeutics | 70.20 Mn | 39.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 221,000.00 |
| Mar 31, 2026 | 811,000.00 |
| Dec 31, 2025 | 750,000.00 |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 880,000.00 |
| Dec 31, 2024 | 573,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 845,000.00 |
| Sep 30, 2022 | 284,000.00 |
| Jun 30, 2022 | 516,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | 176,000.00 |
| Sep 30, 2021 | 70,000.00 |